Abstract Anterior foregut endoderm (AFE) gives rise to therapeutically relevant cell types in tissues such as the esophagus, salivary glands, lung, thymus, parathyroid and thyroid. Despite its importance, reports describing the generation of AFE from pluripotent stem cells (PSCs) by directed differentiation have mainly focused on the Nkx2.1 + lung and thyroid lineages. Here, we describe a novel protocol to derive a subdomain of AFE, identified by expression of Pax9, from PSCs using small molecules and defined media conditions. We generated a reporter PSC line for isolation and characterization of Pax9 + AFE cells, which when transplanted in vivo, can form several distinct complex AFE-derived epithelia, including mucosal glands and stratified squamous epithelium. Finally, we show that the directed differentiation protocol can be used to generate AFE from human PSCs. Thus, this work both broadens the range of PSC-derived AFE tissues and creates a platform enabling the study of AFE disorders.
Introduction
The ability to generate specific tissues from pluripotent stem cells (PSCs) is an important goal for developing human cell replacement therapies and to enable the generation of disease-specific models. While much attention has focused on the derivation of organs involved in metabolic diseases, such as the pancreas and liver, fewer studies have addressed organs derived from anterior foregut endoderm (AFE). Arising from a regional domain of definitive endoderm (DE), the AFE contributes to many organs including the salivary glands, esophagus, stomach, trachea, and lungs. It also gives rise to the pharyngeal endoderm, which in turn forms the thymus, parathyroid glands, thyroid gland and ultimobranchial bodies (Zorn & Wells, 2009) .
One approach to generate specific cell populations is to direct PSCs toward a desired cell type by sequential progression through intermediate cell populations, mimicking the stages of embryonic development. Monolayer differentiation approaches allow homogeneous accessibility of cells to exogenous signals required to guide cell fate decisions. Indeed, monolayer differentiation strategies have been employed to produce definitive endoderm (DE), the precursor of AFE, from PSCs through activation of the wingless (WNT) and TGFβ signaling pathways (Sherwood et al., 2011; D'Amour et al., 2005) . More recently, AFE has been generated from PSCderived definitive endoderm (DE) in vitro and upon further differentiation can be directed to express the lung-and thyroid-specific transcription factor Nkx2.1 (Mou et al., 2012; Longmire et al., 2012; Wong et al., 2012; Green et al., 2011) . The generation of organized AFE epithelia has also been reported, however these are currently limited to respiratory epithelial lineages (Mou et al., 2012; Wong et al., 2012) , necessitating further work to produce additional organized AFE epithelia from PSCs. In order to develop a protocol to produce AFE capable of forming a broader spectrum of AFE-derived epithelia, we selected the transcription factor Pax9 for use as an AFE marker based on its broad expression domain (Fig. 1A) . Pax9 is expressed from e9.0 in the developing murine pharyngeal foregut endoderm and is required for the development of the thymus, parathyroid and ultimobranchial bodies (Peters et al., 1998) . Pax9 expression is retained in several AFE-derived mature cell types including the oral epithelium, salivary glands, parathyroid gland, thymus, esophagus and fore-stomach (Peters et al., 1998) . Although the generation of PAX9+ cell containing AFE cultures has been reported from human PSCs (Green et al., 2011) , upon transplantation, obtained organized epithelial structures expressed genes indicative of lung epithelial cells rather than other PAX9 + AFE derived epithelia. Thus, there is a need to explore alternative approaches to generate PAX9 + cells from PSCs in order to produce the spectrum of PAX9 + AFE epithelia. We report a monolayer differentiation approach using small molecules and chemically defined media to generate PAX9 + AFE cells from both mouse and human PSCs, thereby minimizing the contribution of uncharacterized signals during directed differentiation. Through the use of a novel mouse reporter PSC line, we isolated Pax9 + AFE cells for molecular and functional characterization. Generated Pax9 + AFE cells not only exhibit molecular signatures of anterior and pharyngeal foregut in vitro, but also are competent to form a variety of organized AFE epithelial structures upon transplantation in vivo. Thus, these results advance the AFE differentiation field by generating a transcriptional signature for Pax9 + AFE, broadening the spectrum of AFE epithelia currently generated from PSCs, and creating a platform to study AFE developmental disorders.
Materials and Methods

Mouse pluripotent stem cell culture
All mouse PSC lines; AV3, p2lox40, Sox17 GFP , and Pax9
Venus were maintained on mouse embryonic fibroblasts (MEF) in KO DMEM (GIBCO, 10829) supplemented with 15% Hyclone FBS (Thermo Scientific, SH30070.03), 1% Glutamax (GIBCO, 35050079), 1% NEAA (Cellgro, 25-025-CI), 100 μM β-mercaptoethanol (Invitrogen, 21985023), 1 × 10 3 units/ml ESGRO LIF (Millipore, ESG1107). Cells were fed daily and split every 2-3 days with 0.25% trypsin (GIBCO, 25200114).
Mouse pluripotent stem cell differentiation
Maintenance cultures were split and MEF depleted for 30 min in maintenance media. PSCs were collected and resuspended in differentiation media 1 [A-DMEM (GIBCO, 12491) supplemented with 1% N2 (GIBCO, 17502-048), 2% B27 minus vitamin A (GIBCO, 12587-010), 1% Glutamax (GIBCO, 35050079) 1% P/S (Cellgro, 30-001-CI)] and 10 μM Y-27632 (Selleck Chemicals, S1049). Cells were plated at 5 × 10 3 cells/cm 2 onto 0.1% gelatin-coated 6 well plates. On day 2 cells were fed with differentiation media 1 with 5nM GSK-3 inhibitor XV (Calbiochem, 361558) and 5 μM IDE-1 (Tocris, 4015). On days 3, 4, and 5, cells were fed with differentiation media 2 [A-DMEM (GIBCO, 12491) supplemented with 2% B27 minus vitamin A, 1% Glutamax, 1% P/S] plus 5 μM IDE-1. On day 6 cultures were split with 0.25% trypsin and plated at 3 × 10 5 cells/cm 2 onto 804G conditioned medium-coated plates with 10 μM Y-27632 in differentiation media 2. Cells were treated with 500 nM A83-01 (Tocris, 2939) and 100 nM LDN193189 (Selleck Chemicals, S2618).
Human pluripotent stem cell culture
HUES64 were maintained on mouse embryonic fibroblasts in KO DMEM (GIBCO, 10829) supplemented with 20% KOSR (Invitrogen, 10828-028), 1% Glutamax (GIBCO, 35050079), 1% NEAA (Cellgro, 25-025-CI), 55 μM β-mercaptoethanol (Invitrogen, 21985023), 10 ng/ml bFGF (GIBCO, PH0023). Cells were fed daily and split every 4-5 days with TrypLE Express (GIBCO, 12604).
Human pluripotent stem cell differentiation
Maintenance cultures were split with TrypLE Express and cells plated at 1-1.5 × 10 5 cells/cm 2 onto growth factor reduced matrigel (BD Bioscience, 356231)-coated 6 well plates in mTESR (Stem Cell Technologies, 05850). On day 3, cells were fed with differentiation media [RPMI 1640 (GIBCO, 21870-092) 2% B27 minus vitamin A (GIBCO, 12587-010), 1% Glutamax (GIBCO, 35050079) 1% P/S (Cellgro, 30-001-CI)] supplemented with 5 nM GSK-3 inhibitor XV (Calbiochem, 361558) and 5 μM IDE-1 (Tocris, 4015). On days 4-6, cells were fed with differentiation media supplemented with 5 μM IDE-1. On days 7-13, cells were fed with differentiation media supplemented with 500 nM A83-01 (Tocris, 2939) and 100 nM LDN193189 (Selleck Chemicals, S2618).
Quantitative real time PCR
RNA was isolated using Trizol (Invitrogen, 15596-018) according to the manufacturer's instructions and 2 μg of RNA was reverse transcribed to cDNA using SuperScript III (Invitrogen, 18080-044). 30 ng cDNA was analyzed using Taqman Master Mix (Applied Biosystems, 4440040) and gene specific Taqman assays according to the manufacturer's instructions (table S2). Relative gene expression was calculated using the ΔΔCT method; all genes were normalized to βactin.
Immunofluorescence
Cells were fixed with 4% paraformaldehyde for 30 min at room temperature, washed with PBS, washed with PBS + 0.2% Triton X-100 (PBST), and blocked with 5% donkey serum in PBST (blocking buffer) for 1 h at room temperature. Primary antibodies (Table S3) were diluted in blocking buffer at the indicated concentration and incubated overnight at 4°C. Cells were washed three times in PBST, and incubated with appropriate alexa dye-conjugated secondary antibodies (Invitrogen) diluted 1:300 in blocking buffer at room temperature for 2 h. Cells were washed three times in PBST. Nuclei were stained with Hoechst (Invitrogen, H3570). Images were visualized using a Nikon Ti inverted fluorescence microscope or a Leica TCS SP5 II confocal microscope.
Flow cytometry and cell sorting
Cells were dissociated with 0.25% trypsin and stained with a PE/ Cy7 anti-mouse CD326 EpCAM antibody (Biolegend, 118216) in PBS supplemented with 2% FBS on ice. Flow cytometry was performed using a Beckman Coulter FC500 flow cytometer and dead cells excluded with 7AAD (ebioscience, 00-6993-50). Cell sorting was performed using a Beckman Coulter MoFlo XDP or BD FACSAria II. All data was analyzed using FlowJo (Tree Star, Inc., Ashland, OR).
In vivo maturation assay
1 × 10 5 sorted VENUS + EPCAM + cells were resuspended in 10 μl of recipients' blood and transplanted under the renal capsule of Nu/Nu mice (Jackson Laboratory). After 4-6 weeks, tissues were fixed in 4% paraformaldehyde for 1-2 h at room temperature and incubated in 30% sucrose overnight at 4°C. Tissues were equilibrated in OCT and then frozen in OCT for cryosectioning. Slides were immunostained for markers of mature epithelial cell types (Table S3) .
3. Results 3.1. Definitive endoderm cultures generated from mouse PSCs using small molecules and defined media differentiate into Pax9 expressing anterior foregut endoderm
To minimize contribution of undefined signals, we aimed to develop a novel approach to differentiate DE and AFE from PSCs using chemically defined media with a B27 supplement and small molecules (Fig. 1B) . IDE-1 has previously been shown to replace the TGFβ agonist Activin A in PSC differentiation to DE (Borowiak et al., 2009) , and GSK-3 inhibitor XV has been used in place of Wnt3a in directed differentiation protocols (Sherwood et al., 2011) , however a combinatorial approach of these small molecules to establish defined media conditions has not been explored. Following treatment of monolayer PSC cultures with these molecules, the expression levels of the DE transcription factors Sox17 and FoxA2 were increased and to a lesser extent the AFE-specific transcription factors Pax9 and Pax1 relative to PSCs (Fig. 1C) . In concordance, immunofluorescence staining indicated the generation of endodermal cells coexpressing SOX17 and FOXA2 on day 6 of differentiation (Fig. 1D) , demonstrating that PSCs can be differentiated to DE with small molecules in a chemically defined media.
Previously, Pax9 + AFE has been generated from human ESC derived DE by inhibition of both the BMP and TGFβ signaling pathways with Noggin and the small molecule SB431542, respectively (Green et al., 2011) . Based on these findings, we aimed to generate PAX9 + AFE by treating DE with the BMP inhibitor LDN193189 (BMPi) and the TGFβ inhibitor A83-01 (TGFβi) (Fig. 1B) . Inclusion of Rock inhibitor (Y-27632) was used to increase cell survival during plating. Treating DE cultures with BMPi and TGFβi for 3 days resulted in decreased expression of Sox17 and FoxA2, and increased expression of Pax9 and Pax1 relative to DE cultures (Fig. 1C) . Immunofluoresence staining demonstrated that PAX9 cells generated by this small molecule and defined media approach also expressed the AFE markers EPCAM, SOX2 and FOXA2 (Fig. 1E) . To test the hypothesis that the addition of BMP and TGFβ inhibitors to the cultures is required to generate AFE from mouse PSCs, we omitted this treatment from days 6-9. We found that on day 9 of differentiation, cultures contained PAX9 + EPCAM + cells, and clusters of PAX9 cells also expressed SOX2 and FOXA2, (Fig. S1) , leaving open the possibility that exogenous inhibition of BMP and TGFβ signaling may not be required under these culture conditions. We conclude that Pax9 + AFE can be produced using a novel small molecule directed monolayer differentiation protocol.
Generation of a novel Pax9
Venus reporter cell line enables the isolation and quantification of Pax9 Venus reporter cell line expressed VENUS in the pharyngeal endoderm and somites at e10.5 (Fig. S2D) , consistent with the known expression pattern of Pax9 (Peters et al., 1998 Venus mice affected the VENUS expression pattern, we generated Pax9
Venus and Pax9
VenusΔneo mice and analyzed VENUS expression at e9.5 (Fig. S3) . We concluded that embryos with and without the neomycin resistance cassette had comparable VENUS expression patterns at e9.5. We applied the small molecule and defined media differentiation protocol to the Pax9
Venus reporter cell line to enable the sorting and quantification of Pax9 expressing epithelial cells. Only background levels of VENUS expression were detected in PSC cultures ( Fig. 2A) . However, following GSK-3 inhibitor XV and IDE-1 treatment, EPCAM + cells separated into two distinct cell populations with VENUS + EPCAM + cells representing 0.7 ± 0.08% of the culture ( Figs. 2A and B) . DE cultures generated with the Pax9 Venus reporter contained 36.2 ± 5.8% SOX17 cells (Fig. S4A) . On day 9 of differentiation, cultures without BMPi and TGFβi had statistically indistinguishable percentages of VENUS + cells compared to those treated with BMPi and TGFβi and during days 6-9 of differentiation (6.8 ± 2.4% and 6.0 ± 1.6% respectively). EpCAM expression on PSCs and DE, as well as the presence of VENUS -EPCAM + cells in AFE cultures precludes the use of EpCAM as a unique marker for isolating Pax9 + AFE. Cell cultures expanded approximately 20-fold from PSC to DE and an additional 3-fold from DE to AFE (Fig. S4B) . The VENUS + cells generated in vitro coexpress PAX9, supporting the faithfulness of the reporter (Fig. 2C and Fig. S5A ). In conclusion, VENUS + EPCAM + cells can be generated using the small molecule and defined media protocol, enabling both an accurate quantification of Pax9 + AFE cells and the isolation of Pax9 + AFE from in vitro cultures.
Pax9 VENUS + cells express an anterior foregut gene expression signature
To gain a more detailed understanding of the molecular characteristics of our DE and AFE populations, we performed transcriptional profiling by microarray. To that end, we purified PSCs, DE, and AFE from our differentiation cultures through the use of Sox17 GFP + and Pax9 Venus reporter cell lines. We sorted Sox17 GFP + EPCAM + cells from day 6 (DE) cultures and Pax9 VENUS + EPCAM + cells from day 9 (AFE) cultures for comparison with MEF-depleted PSCs.
Differential expression analysis identified 2976 genes differentially expressed at p b 0.001 across the three populations that clearly separated them from each other (Fig. 2D) . Notably, PSCs clustered separately from Sox17 GFP +
DE and Pax9
VENUS + AFE underscoring a higher degree of similarity between Sox17 GFP + DE and Pax9 VENUS + AFE. Unsupervised clustering of the differentially expressed genes revealed 12 distinct expression patterns that include a gene cluster active in PSC only (enriched for stem cell maintenance genes p = 9.5 × 10 −7 ), genes upregulated in Sox17 GFP + DE only (enriched for endoderm developmental genes, p = 3.1 × 10 −8 ) and an Pax9 VENUS + AFE specific gene cluster (enriched for genes involved in epithelium development, p = 5.5 × 10 −7 ) ( Table S1 ). As expected, pluripotency markers Pou5f1, Nanog and Sox2 were highly expressed in PSCs, while Sox17 GFP + DE was enriched for many known endoderm markers including Sox17, Mixl1, Cer1, Hhex and FoxA2 (Fig. 2E) . Although Pax9 is expressed in a subdomain of AFE, Pax9 is also expressed in several other cell lineages (Peters et al., 1998) . Therefore, to determine which population of Pax9 + cells we had generated in vitro, we examined the expression of key transcription factors in known Pax9 + lineages. We found that the Pax9 VENUS + EPCAM + population expressed higher levels of the AFE and pharyngeal markers Tbx1, Eya1, Six1, Pax1, Vgll2, and Rhox4b (Gordon & Manley, 2011; Mielcarek et al., 2002; Jackson et al., 2003) 
Upon transplantation, Pax9
+ foregut endoderm can organize into AFE-derived complex epithelial cell types
To ascertain the differentiation potential of our in vitro derived AFE, we transplanted sorted Pax9 VENUS + EPCAM + AFE cells from day 9 directed differentiation cultures under the kidney capsule of immunocompromised mice. Four weeks after transplantation the transplants were removed and several distinct complex epithelial structures expressing VENUS were identified. VENUS + cells retained EPCAM expression and were part of epithelial structures (Fig. 3A) . VENUS + cartilage or mesenchyme was not present in the transplants, reflecting the absence of other non-AFE Pax9 + lineages within the Pax9 VENUS + AFE population. As expected from the genetic linkage of reporter and Pax9 expression, VENUS + epithelia contained PAX9 + cells (Fig. 3B) . VENUS + stratified squamous epithelia were identified in the transplant (Fig. 3C ) consistent with Pax9 + stratified squamous epithelium that develops from the columnar AFE and lines the pharynx and esophagus (Yu et al., 2005) . The presumptive esophageal endoderm initially expresses keratin 8 (K8) but is replaced with keratin 14 (K14) originating in the basal layers during stratification (Yu et al., 2005) . Stratified squamous epithelia found in the transplant expressed K14 in the basal layers, and K8 in the apical cell layer (Fig. 3D) . VENUS + pseudostratified columnar epithelium and glandular structures were found in the transplant. These structures contained cells that stained positive for alcian blue, indicative of mucosal cells (Figs. 3E, F, H and I) and SOX2 was expressed in these mucosal epithelial cells (Fig. 3G) . Since Pax9 expression is retained in the mucosal salivary glands of adult mice (Peters et al., 1998) , and the VENUS + mucosal glands morphologically resemble the sublingual and minor salivary glands and tracheal submucosal glands, we stained for salivary mucin 19 (MUC19). MUC19 was detected on the apical surface of VENUS + mucosal epithelia (Fig. 3J ) consistent with its known expression in the salivary glands and the tracheal submucosal glands (Das et al., 2010) .
To determine whether any of these VENUS + epithelia contained mature 3rd pharyngeal pouch derivatives, we looked for expression of the parathyroid marker Gcm2, and the thymus marker FoxN1, but did not detect GCM2 or FOXN1 in the transplants.
We conclude that upon transplantation, VENUS + EPCAM + AFE generated with small molecules is capable of differentiation and organization into several distinct epithelial types, including stratified squamous epithelium, pseudostratified columnar epithelium and mucosal glands.
3.5. Pax9 + anterior foregut endoderm can be produced from human PSCs using small molecules and defined media Since many important organs including the thymus, parathyroid and thyroid are derived from Pax9 + AFE, protocols to generate these cells from PSCs would allow the study of diseases affecting these organs and potentially generate specific cell types for therapy. To produce Pax9 + AFE from human PSCs, we adjusted the timing of our small molecule and defined media directed differentiation protocol (Fig. 4A) . As with mouse PSCs, the human embryonic stem cell line HUES64 could be differentiated to 48.7 ± 7.8% DE with the small molecules GSK-3 inhibitor XV and IDE-1 as judged by coexpression of FOXA2 and SOX17 (Figs. S6A and S6B) . Following the treatment of DE cultures with BMPi and TGFβi, PAX9 could be detected (Fig. 4B ) and PAX9 cells coexpressing EPCAM, SOX2, FOXA2 and TBX1 and were readily identified (Fig. 4C) . Increases in transcript levels of TBX1, EYA1 and SIX1 relative to day 4 DE cultures were also detected, consistent with an AFE specification (Fig. S6C) . Therefore, Pax9 + AFE can be generated using small molecule and defined media from human PSCs.
Discussion
The generation of specific AFE-derived cells allow for novel cell therapies and human disease models for diseases affecting organs originating from the anterior foregut endoderm. Here, we report a defined media and small molecule-based differentiation protocol to produce Pax9 + AFE from PSCs that when matured in vivo are competent to organize into several distinct types of anterior foregut epithelia. This generation of a small-molecule directed, defined protocol will be beneficial for future production of cells for replacement therapies, and to advance the understanding of the essential signals required for differentiation. This protocol presents a significant advance over previous protocols designed to generate PAX9 + AFE, as the AFE cells generated in this report have the potential to give rise to multiple AFE-derived organized PAX9 + epithelial structures including stratified squamous epithelium, pseudostratified columnar epithelium and mucosal glands.
The use of a novel Pax9Venus reporter PSC line allowed the purification of PSC-derived Pax9 + AFE for molecular analysis and enabled the comparison to embryonic Pax9 + AFE. The expression of several pharyngeal endoderm transcription factors in PSC-derived Pax9 + AFE suggests that these cells may have the capacity to differentiate into pharyngeal foregut derivatives. Interestingly, expression levels of several pharyngeal foregut-specific transcription factors were higher in the embryonic Pax9 + AFE than in PSC-derived Pax9 + AFE. It is therefore possible that in vitro Pax9 + AFE represents a more immature cell population and yet to be identified signals are required to specify pharyngeal endoderm derived organ domains.
Although we included BMPi and TGFβi in our directed differentiation protocol, consistent with the published PAX9 + AFE generating protocol, our data suggests that these inhibitors may not be required to specify Pax9 + AFE from DE for mouse PSCs. In concordance, other directed differentiation protocols did not rely on exogenous BMP inhibition (Mou et al., 2012) or TGFβ inhibition (Wong et al., 2012) to generate FOXA2 + SOX2 + AFE cells from PSCs. Thus, further work is needed to determine the context in which BMP and TGFβ inhibition are necessary for the generation of functional Pax9 + AFE. Importantly, the small molecule and defined media approach used for mouse PSCs was successfully applied to human PSCs, enabling future work to generate human disease models or to allow the development of novel cell therapies. Such models could be beneficial to increased understanding of pharyngeal developmental defects, such as DiGeorge Syndrome, or Type 1 diabetes, where dysfunction of pharyngeal endoderm derived-thymic epithelial cells may contribute to a defective central tolerance induction. 
Conclusions
We utilized small molecules and chemically defined media to generate PAX9 + AFE cells from mouse and human PSCs. Through the use of a novel reporter Pax9
Venus mouse PSC line, we isolated PSC-derived PAX9 + EPCAM + cells that had a gene expression signature consistent with Pax9 + AFE. Upon transplantation in vivo, these cells formed a variety of organized epithelial structures including Pax9 + stratified squamous epithelium, pseudostratified columnar epithelium and mucosal glands. We were able to modify the differentiation protocol for the human stem cell line HUES64, thereby enabling future work on human disease modeling and cell replacement therapies.
Supplementary data to this article can be found online at http://dx.doi.org/10.1016/j.scr.2013.06.007.
